Breda, the Netherlands / Ghent, Belgium– arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it will report its fourth quarter business update and its full year 2014 financial results after market close on Wednesday, 18 March 2015.
The arGEN-X management team will host a conference call and audio webcast at 6:00pm CET / 1:00pm EDT to discuss the financial results, as well as provide a fourth quarter business update.
